Cargando…
Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells
BACKGROUND: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymph...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008436/ https://www.ncbi.nlm.nih.gov/pubmed/24795534 http://dx.doi.org/10.1186/1475-2867-14-35 |
_version_ | 1782314449270472704 |
---|---|
author | Miller, Aaron L Geng, Chuandong Golovko, Georgiy Sharma, Meenakshi Schwartz, Jason R Yan, Jiabin Sowers, Lawrence Widger, William R Fofanov, Yuriy Vedeckis, Wayne V Thompson, E Brad |
author_facet | Miller, Aaron L Geng, Chuandong Golovko, Georgiy Sharma, Meenakshi Schwartz, Jason R Yan, Jiabin Sowers, Lawrence Widger, William R Fofanov, Yuriy Vedeckis, Wayne V Thompson, E Brad |
author_sort | Miller, Aaron L |
collection | PubMed |
description | BACKGROUND: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymphoid malignancies are sensitive to GC-driven apoptosis. Resistance to GCs can be a significant clinical problem, however, and correlates with resistance to several other major chemotherapeutic agents. METHODS: We analyzed the effect of treatment with the cytosine analogue 5 aza-2’ deoxycytidine (AZA) on GC resistance in two acute lymphoblastic leukemia (T or pre-T ALL) cell lines- CEM and Molt-4- and a (B-cell) myeloma cell line, RPMI 8226. Methods employed included tissue culture, flow cytometry, and assays for clonogenicity, cytosine extension, immunochemical identification of proteins, and gene transactivation. High throughput DNA sequencing was used to confirm DNA methylation status. CONCLUSIONS: Treatment of these cells with AZA resulted in altered DNA methylation and restored GC-evoked apoptosis in all 3 cell lines. In CEM cells the altered epigenetic state resulted in site-specific phosphorylation of the GR, increased GR potency, and GC-driven induction of the GR from promoters that lie in CpG islands. In RPMI 8226 cells, expression of relevant coregulators of GR function was altered. Activation of p38 mitogen-activated protein kinase (MAPK), which is central to a feed-forward mechanism of site-specific GR phosphorylation and ultimately, apoptosis, occurred in all 3 cell lines. These data show that in certain malignant hematologic B- and T-cell types, epigenetically controlled GC resistance can be reversed by cell exposure to a compound that causes DNA demethylation. The results encourage studies of application to in vivo systems, looking towards eventual clinical applications. |
format | Online Article Text |
id | pubmed-4008436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40084362014-05-03 Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells Miller, Aaron L Geng, Chuandong Golovko, Georgiy Sharma, Meenakshi Schwartz, Jason R Yan, Jiabin Sowers, Lawrence Widger, William R Fofanov, Yuriy Vedeckis, Wayne V Thompson, E Brad Cancer Cell Int Primary Research BACKGROUND: Glucocorticoids (GCs) are often included in the therapy of lymphoid malignancies because they kill several types of malignant lymphoid cells. GCs activate the glucocorticoid receptor (GR), to regulate a complex genetic network, culminating in apoptosis. Normal lymphoblasts and many lymphoid malignancies are sensitive to GC-driven apoptosis. Resistance to GCs can be a significant clinical problem, however, and correlates with resistance to several other major chemotherapeutic agents. METHODS: We analyzed the effect of treatment with the cytosine analogue 5 aza-2’ deoxycytidine (AZA) on GC resistance in two acute lymphoblastic leukemia (T or pre-T ALL) cell lines- CEM and Molt-4- and a (B-cell) myeloma cell line, RPMI 8226. Methods employed included tissue culture, flow cytometry, and assays for clonogenicity, cytosine extension, immunochemical identification of proteins, and gene transactivation. High throughput DNA sequencing was used to confirm DNA methylation status. CONCLUSIONS: Treatment of these cells with AZA resulted in altered DNA methylation and restored GC-evoked apoptosis in all 3 cell lines. In CEM cells the altered epigenetic state resulted in site-specific phosphorylation of the GR, increased GR potency, and GC-driven induction of the GR from promoters that lie in CpG islands. In RPMI 8226 cells, expression of relevant coregulators of GR function was altered. Activation of p38 mitogen-activated protein kinase (MAPK), which is central to a feed-forward mechanism of site-specific GR phosphorylation and ultimately, apoptosis, occurred in all 3 cell lines. These data show that in certain malignant hematologic B- and T-cell types, epigenetically controlled GC resistance can be reversed by cell exposure to a compound that causes DNA demethylation. The results encourage studies of application to in vivo systems, looking towards eventual clinical applications. BioMed Central 2014-04-23 /pmc/articles/PMC4008436/ /pubmed/24795534 http://dx.doi.org/10.1186/1475-2867-14-35 Text en Copyright © 2014 Miller et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research Miller, Aaron L Geng, Chuandong Golovko, Georgiy Sharma, Meenakshi Schwartz, Jason R Yan, Jiabin Sowers, Lawrence Widger, William R Fofanov, Yuriy Vedeckis, Wayne V Thompson, E Brad Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
title | Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
title_full | Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
title_fullStr | Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
title_full_unstemmed | Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
title_short | Epigenetic alteration by DNA-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
title_sort | epigenetic alteration by dna-demethylating treatment restores apoptotic response to glucocorticoids in dexamethasone-resistant human malignant lymphoid cells |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008436/ https://www.ncbi.nlm.nih.gov/pubmed/24795534 http://dx.doi.org/10.1186/1475-2867-14-35 |
work_keys_str_mv | AT milleraaronl epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT gengchuandong epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT golovkogeorgiy epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT sharmameenakshi epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT schwartzjasonr epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT yanjiabin epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT sowerslawrence epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT widgerwilliamr epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT fofanovyuriy epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT vedeckiswaynev epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells AT thompsonebrad epigeneticalterationbydnademethylatingtreatmentrestoresapoptoticresponsetoglucocorticoidsindexamethasoneresistanthumanmalignantlymphoidcells |